Chengdu Yuandong Pharmaceutical

Chengdu Easton Biopharmaceuticals is a high-tech pharmaceutical company based in Chengdu, China, specializing in the research, development, production, and commercialization of chemical raw materials, high-end generics, and innovative small-molecule drugs. Founded in 2009 and listed on the Shanghai Stock Exchange STAR Market in 2020, the company focuses on critical therapeutic areas including anesthesia and pain management, cardiovascular diseases, oncology, and diabetes. Its robust portfolio features over 20 industrialized chemical drugs and a growing pipeline of innovative candidates, such as the Phase 3 DPP-4 inhibitor yogliptin for type 2 diabetes. Easton Biopharmaceuticals maintains a strong international presence, with several products certified by the US FDA and EU EMA, and is actively expanding into biological drug development.